The pharmaceutical company Astrazeneca could have clarity about the effectiveness of its corona vaccine by the end of the year. If the interrupted study can continue, you should know before the end of the year whether the vaccine protects against the virus, said CEO Pascal Soriot in a conference call. It happens very often that studies have to be interrupted, the difference this time is only that the whole world is ing. Astrazeneca had interrupted the studies with its corona vaccine candidate, which the World Health Organization sees as one of the most promising, because of an unexplained disease in a study participant. According to media reports, the test person suffers from transverse myelitis — an inflammation of the spinal cord that is often caused by viral infections. Soriot said it was not yet clear if it was transverse myelitis and more tests were needed. The process will be reviewed by an independent committee that will decide whether the study will continue.